Chicken Eggs Used as Bioreactors for Pharmaceutical Protein Production

Developments in biotechnology have led to the use of chicken eggs as platforms for producing pharmaceutical proteins, offering an alternative to traditional manufacturing methods.

Biotech companies have investigated genetic engineering techniques to enable hens to generate human or veterinary therapeutic proteins within their eggs. This approach involves modifying hens so that their eggs contain specific proteins, which can then be extracted for pharmaceutical use.

One project supported by the U.S. Department of Agriculture focused on creating transgenic chickens capable of expressing human pharmaceutical proteins in their eggs. The project achieved more than 50% transgenic offspring through testicular injection and over 90% through cardiac injection in female chickens, according to project documentation.

In addition to genetic engineering, other methods have been explored to enhance the efficiency of egg-based production systems. An Irish biotechnology company, Ovagen, developed a germ-free embryonated chicken egg platform. In a comparative study conducted at The Pirbright Institute, this platform demonstrated the ability to produce up to 7,600 doses of yellow fever virus 17D vaccine per egg.

What the numbers show

• Over 50% transgenic offspring were produced via testicular injection in a USDA-supported project
• Cardiac injection in female chickens resulted in over 90% transgenic offspring
• Ovagen’s germ-free eggs yielded up to 7,600 yellow fever vaccine doses per egg

The concept of using transgenic hens for drug production has been proposed as a way to reduce costs compared to conventional bioreactor systems. This method aims to streamline the manufacturing process for certain pharmaceutical proteins by leveraging the natural capabilities of egg-laying hens.

Egg-based vaccine production is not a new practice. Since the 1930s, fertilized chicken eggs have been used to manufacture vaccines, including those for influenza. This technique remains a cost-effective option for producing vaccines on a large scale.

Comparative studies have shown that both traditional and genetically engineered egg platforms can yield high volumes of pharmaceutical products. The use of germ-free eggs, as demonstrated by Ovagen, represents an additional step in optimizing production efficiency and consistency.

Biotech research continues to explore the potential of chicken eggs as bioreactors, with ongoing projects aiming to refine genetic engineering methods and improve output. These efforts are part of a broader trend toward alternative protein production systems in the pharmaceutical industry.

* This article is based on publicly available information at the time of writing.